195 related articles for article (PubMed ID: 30068316)
41. Bayesian inference for age-structured population model of infectious disease with application to varicella in Poland.
Gwiazda P; Miasojedow B; Rosińska M
J Theor Biol; 2016 Oct; 407():38-50. PubMed ID: 27396357
[TBL] [Abstract][Full Text] [Related]
42. Surrogate-based Bayesian calibration of biomechanical models with isotropic material behavior.
Römer U; Liu J; Böl M
Int J Numer Method Biomed Eng; 2022 Apr; 38(4):e3575. PubMed ID: 35094499
[TBL] [Abstract][Full Text] [Related]
43. A two-component model for counts of infectious diseases.
Held L; Hofmann M; Höhle M; Schmid V
Biostatistics; 2006 Jul; 7(3):422-37. PubMed ID: 16407470
[TBL] [Abstract][Full Text] [Related]
44. Optimal intervention for an epidemic model under parameter uncertainty.
Clancy D; Green N
Math Biosci; 2007 Feb; 205(2):297-314. PubMed ID: 17070866
[TBL] [Abstract][Full Text] [Related]
45. Bayesian inference of biochemical kinetic parameters using the linear noise approximation.
Komorowski M; Finkenstädt B; Harper CV; Rand DA
BMC Bioinformatics; 2009 Oct; 10():343. PubMed ID: 19840370
[TBL] [Abstract][Full Text] [Related]
46. Probabilistic cost-effectiveness analysis of HIV prevention. Comparing a Bayesian approach with traditional deterministic sensitivity analysis.
Johnson-Masotti AP; Laud PW; Hoffmann RG; Hayat MJ; Pinkerton SD
Eval Rev; 2001 Aug; 25(4):474-502. PubMed ID: 11480309
[TBL] [Abstract][Full Text] [Related]
47. Desirable BUGS in models of infectious diseases.
Auzenbergs M; Correia-Gomes C; Economou T; Lowe R; O'Reilly KM
Epidemics; 2019 Dec; 29():100361. PubMed ID: 31668494
[TBL] [Abstract][Full Text] [Related]
48. Bayesian model choice for epidemic models with two levels of mixing.
Knock ES; O'Neill PD
Biostatistics; 2014 Jan; 15(1):46-59. PubMed ID: 23887980
[TBL] [Abstract][Full Text] [Related]
49. Calibration of complex models through Bayesian evidence synthesis: a demonstration and tutorial.
Jackson CH; Jit M; Sharples LD; De Angelis D
Med Decis Making; 2015 Feb; 35(2):148-61. PubMed ID: 23886677
[TBL] [Abstract][Full Text] [Related]
50. Modeling HIV-1 dynamics and fitness in cell culture across scales.
Immonen T; Somersalo E; Calvetti D
Bull Math Biol; 2014 Feb; 76(2):486-514. PubMed ID: 24510727
[TBL] [Abstract][Full Text] [Related]
51. Model discrimination in dynamic molecular systems: application to parotid de-differentiation network.
Kim J; Li J; Venkatesh SG; Darling DS; Rempala GA
J Comput Biol; 2013 Jul; 20(7):524-39. PubMed ID: 23829652
[TBL] [Abstract][Full Text] [Related]
52. Survival models in health economic evaluations: balancing fit and parsimony to improve prediction.
Jackson CH; Sharples LD; Thompson SG
Int J Biostat; 2010; 6(1):Article 34. PubMed ID: 21969987
[TBL] [Abstract][Full Text] [Related]
53. Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases: the BEST study.
Favato G; Baio G; Capone A; Marcellusi A; Costa S; Garganese G; Picardo M; Drummond M; Jonsson B; Scambia G; Zweifel P; Mennini FS
Med Care; 2012 Dec; 50(12):1076-85. PubMed ID: 22922435
[TBL] [Abstract][Full Text] [Related]
54. Calibrating models in economic evaluation: a comparison of alternative measures of goodness of fit, parameter search strategies and convergence criteria.
Karnon J; Vanni T
Pharmacoeconomics; 2011 Jan; 29(1):51-62. PubMed ID: 21142278
[TBL] [Abstract][Full Text] [Related]
55. Comparison of the expected rewards between probabilistic and deterministic analyses in a Markov model.
Xie X; Yeung MW; Wang Z; Wang M; Gajic-Veljanoski O; Ng V; Volodin A
Expert Rev Pharmacoecon Outcomes Res; 2020 Apr; 20(2):169-175. PubMed ID: 31116609
[No Abstract] [Full Text] [Related]
56. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease.
Menn P; Leidl R; Holle R
Pharmacoeconomics; 2012 Sep; 30(9):825-40. PubMed ID: 22799876
[TBL] [Abstract][Full Text] [Related]
57. Parallel Markov chain Monte Carlo - bridging the gap to high-performance Bayesian computation in animal breeding and genetics.
Wu XL; Sun C; Beissinger TM; Rosa GJ; Weigel KA; Gatti Nde L; Gianola D
Genet Sel Evol; 2012 Sep; 44(1):29. PubMed ID: 23009363
[TBL] [Abstract][Full Text] [Related]
58. Inclusion of the value of herd immunity in economic evaluations of vaccines. A systematic review of methods used.
Nymark LS; Sharma T; Miller A; Enemark U; Griffiths UK
Vaccine; 2017 Dec; 35(49 Pt B):6828-6841. PubMed ID: 29146380
[TBL] [Abstract][Full Text] [Related]
59. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
[TBL] [Abstract][Full Text] [Related]
60. A full Bayesian model to handle structural ones and missingness in economic evaluations from individual-level data.
Gabrio A; Mason AJ; Baio G
Stat Med; 2019 Apr; 38(8):1399-1420. PubMed ID: 30565727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
